BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Falcon Genomics Awarded Patent for Innovative Cancer Test


5/29/2009 7:34:26 AM

Bookmark and Share

PITTSBURGH, May 28 /PRNewswire/ -- Falcon Genomics, Inc. announced today that it has received U.S. Patent # 7,537,913 with claims covering the Company's Cancer BioChip System (CBCS) for the identification and validation of potential cancer targets in a high-throughput in vitro setting with great clinical translational potential.

The patent claims are supported by experimental validation with human breast cancer cells using Falcon Genomics' first-generation Cancer BioChip System (CBC-1). These results, recently presented at the 6th Annual Conference on Cancer Drugs Research and Development in Philadelphia, PA (February 19, 2009) represent the first reported use of high-throughput one-step delivery of silencing RNA (siRNA) into cells growing in an anchorage-independent manner with real-time evaluation of cell growth.

"Cancer is analogous to a physiological train-wreck. It only takes a small number of defective signals to trigger the multitudes of abnormal molecular profiles observed within cancer cells. Triggering molecules are the ones that must be targeted for therapy," said Dr. Rula Abbud-Antaki, President and Chief Scientific Officer of Falcon Genomics. "Our proprietary technology will provide personalized identification of cancer- initiating events, and formulation of efficient and accurate therapies."

According to Dr. Peter D. Mlynek, a patent attorney with the law firm of Eckert Seamans, the Cancer BioChip System is a unique and highly useful technology. "The U.S. Patent Office has found the claimed CBCS to be novel and non-obvious."

About Falcon Genomics, Inc.

Falcon Genomics, Inc. is a private Pittsburgh-based biotech company founded in August 2004. The goal of the company is to provide cutting edge technologies, including functional genomics, for the accurate diagnosis of cancer patients and the personalized formulation of therapeutic strategies. Falcon Genomics currently provides CBCS services for research and pharmaceutical institutions working at the forefront of cancer diagnostics and therapeutics.

For more information, please visit: www.falcongenomics.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES